@Article{,
AUTHOR = {Jorge E. Garcia, David D. Thiel, Gregory A. Broderick},
TITLE = {BCG pyelonephritis following intravesical therapy for transitional cell carcinoma},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {14},
YEAR = {2007},
NUMBER = {2},
PAGES = {3523--3525},
URL = {http://www.techscience.com/CJU/v14n2/62421},
ISSN = {1488-5581},
ABSTRACT = {Bacillus Calmette-Guerin (BCG) is a common
intravesical agent utilized for superficial transitional cell
carcinoma of the bladder. The potential for side effects
and complications does exist secondary to the utilization
of live attenuated bacteria. We present the case of a 70-
year old male that developed BCG pyelonephritis and
associated renal mass following the fifth of six weekly
intravesical BCG therapies. The patient improved
clinically and renal mass resolved following 3 months of
isoniazid monotherapy without renal biopsy.},
DOI = {}
}